Health Canada has given the green light to the first generic version of Novo Nordisk’s Ozempic drug. The approval was granted to Indian drugmaker Dr. Reddy’s Laboratories for their generic semaglutide injection. Health Canada conducted a thorough review and confirmed that the generic drug meets safety, efficacy, and quality standards.
Dr. Kaberi Dasgupta, a physician-scientist and professor at McGill University, expressed enthusiasm about the approval, noting that generic medications typically lead to substantial price reductions compared to brand-name drugs.
Many patients and healthcare providers have been eagerly anticipating a generic version of Ozempic for treating Type 2 diabetes and weight loss. A recent survey indicated that millions of Canadian adults are using GLP-1 drugs such as Ozempic and Mounjaro, with cost being a significant barrier to access.
In addition to its primary uses, researchers are exploring the potential of Ozempic in addressing addictions to substances like alcohol and opioids. Health Canada specified that the generic semaglutide is intended for once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels and is pharmaceutically equivalent to the brand-name product.
The availability of generic drugs is expected to bring about cost savings for patients and the healthcare system. Novo Nordisk’s exclusive rights to semaglutide ended in January, paving the way for generic competition and potentially significant cost reductions for patients.
Mina Tadrous, an associate professor at the University of Toronto specializing in drug policy, highlighted the potential for substantial cost savings with the approval of additional generic drugs. Health Canada emphasized that generic medications are typically 45 to 90 percent cheaper than their brand-name counterparts.
Experts anticipate that with more generics entering the market, prices could drop further, providing more affordable options for patients. However, caution is advised in the use of semaglutide, emphasizing the need for proper medical supervision, diet, and exercise when using the medication to avoid potential harms.
The timeline for the availability of Dr. Reddy’s generics in the market remains uncertain. Health Canada is currently evaluating several other generic submissions and plans to make decisions on them in the coming weeks and months while continuing to monitor the safety and effectiveness of all generic semaglutides.